Scleroderma Queensland
  • Home
  • About Us
    • Your Committee
    • Members' Stories
  • Become a Member
    • Printable Membership Form
    • Online Membership Form
  • Donations
  • RESEARCH
  • FUNDRAISING
  • News
  • EVENTS
  • Group Meetings
  • GET SUPPORT
  • RESOURCES
  • Contact Us
  • Newsletter

Blood-clotting protein FXIII linked to Raynaud’s in SSc patients

15/5/2023

 
Raynaud's phenomenon is a common systemic sclerosis symptom by Steve Bryson, PhD 
Picture
​Elevated activity of a blood-clotting protein called Factor XIII (FXIII) in the bloodstream of adults with systemic sclerosis (SSc) is tied to the presence of Raynaud’s phenomenon, a common SSc symptom, a small study suggests.
While most study participants had FXIII activity levels within the normal range, “patients with higher FXIII activity are more likely to have circulatory disorders in their hands,” the researchers noted.
​
The study, “Factor XIII and Endothelial Dysfunction in Patients with Systemic Sclerosis,” was published in the journal Hämostaseologie.

Read More

Doctors’ lack of knowledge a hurdle in juvenile scleroderma diagnosis

15/5/2023

 
In survey, caregivers highlight key barriers to diagnosis, treatment by Steve Bryson, PhD 
Picture
Caregivers of children with juvenile scleroderma cited a lack of knowledge about the rare disease within the medical community as the primary barrier to a proper diagnosis and treatment, according to a new survey study.

For more than a quarter of the children, it took more than a year from the first symptoms to get a correct diagnosis. Misdiagnoses — ranging from allergies to eczema to a congenital overgrowth disorder — were commonly reported.

Other major hurdles reported by almost all respondents included finding reliable information about scleroderma — especially regarding pediatric patients — juggling work and the child’s healthcare needs, side effects of medications, and balancing care and school.

“Identifying key care barriers will help direct efforts to address needs, reduce disparities in care, and improve patient outcomes,” the researchers wrote, noting that delays in diagnosis and treatment “have been associated with more persistent disease activity, higher damage scores, and higher relapse rates.”

The survey study, “Barriers to care in juvenile localized and systemic scleroderma: an exploratory survey study of caregivers’ perspectives,” was published in the journal Pediatric Rheumatology.

​Wrong diagnosis common for many children with scleroderma
Juvenile scleroderma is a rare type of childhood scleroderma. Most cases are characterized by localized hardened patches of skin, particularly on the arms, legs, or trunk (torso). In more severe cases, the disease can affect organs throughout the body — this is known as systemic scleroderma — including the heart, kidneys, and blood vessels. In some children, these symptoms can be life-threatening.

Late diagnoses are common, with reported wait times of up to three years. Resulting delays in treatment have been linked to more and lasting disease activity, more tissue and organ damage, and more relapses.

The objective of this study, conducted as an online survey, was to investigate the obstacles caregivers encounter when attempting to access specialized care and treatment for children with juvenile scleroderma.
​

“This information could then guide future efforts to develop effective interventions to reduce diagnostic and treatment delays,” the researchers noted.

Read More

Protein-protein interactions linked to pulmonary involvement in SSc

7/5/2023

 
Study targets correlations among SSc patients with different types of lung disease by Andrea Lobo, PhD 
Picture
The degree of skin tightening is associated with changed levels of proteins implicated in inflammation and cell death among systemic sclerosis (SSc) patients with pulmonary involvement, a study in India reports.

The study established protein correlations among SSc patients with different types of lung disease, which might contribute to identifying lung involvement in people with newly diagnosed SSc, the team suggested.

“A longitudinal follow up in these patients with assessment of these immunological parameters may be helpful in monitoring the disease,” the researchers wrote.

The study, “A comparative study of modulatory interaction between cytokines and apoptotic proteins among Scleroderma patients with and without pulmonary involvement,” was published in the journal Cytokine.

SSc is characterized by abnormal scarring of the skin and potentially internal organs, such as the heart, kidney, lungs, and digestive tract.

The disease is thought to develop from the combination of immune dysfunction — meaning the activation and recruitment of immune cells and the production of self-targeting antibodies (fibrosis) — and damage to small blood vessels.

The most prominent forms of lung involvement in SSc are interstitial lung disease (ILD), a group of conditions characterized by lung inflammation and fibrosis, and pulmonary arterial hypertension (PAH), caused by the narrowing of small blood vessels that transport blood to the lungs.

Studies have reported the involvement of proinflammatory and pro-fibrotic signaling molecules called cytokines in SSc. Also implicated in the disease are proteins associated with apoptosis — programmed cell death (as opposed to cell death caused by injury), which can alter immune responses.
​
To investigate the possible correlation between blood cytokines and apoptotic proteins in SSc, researchers in India analyzed 100 treatment-naïve SSc patients, with or without pulmonary involvement, as well as 100 healthy people who served as controls.

Read More

Microparticles shed from cells may be linked with SSc: Study

7/5/2023

 
Levels may serve as biomarkers for the disease, help predict outcomes by Steve Bryson, PhD 
Picture
Levels of microparticles, tiny molecule-filled sacs shed from cells, were altered in the bloodstream of adults with systemic sclerosis (SSc), a study reports.

Elevated microparticles derived from blood-clotting platelets were associated with disease-related antibodies and longer disease duration. By contrast, lower levels of microparticles shed from endothelial cells that line blood vessels were tied to worse skin and blood vessel involvement.

These results suggest microparticles may participate in developing SSc and serve as biomarkers to predict outcomes, the researchers noted in “Microparticles: potential new contributors to the pathogenesis of systemic sclerosis?” which was published in Advances in Rheumatology.

SSc, also called scleroderma, is an autoimmune disease that may affect multiple systems in the body. It’s marked by scar tissue building up in the skin and/or several organs, such as the heart, lungs, kidney, and digestive tract.

Microparticles (MPs), or microvesicles, are tiny membrane-bound sacs shed from cells undergoing activation or apoptosis (programmed cell death), which contain cell type-specific components. Mostly shed from platelets, white blood cells, and endothelial cells, MPs have been shown to modulate inflammatory and blood clotting activities.
​
Studies have suggested that people with SSc have higher levels of MPs in their blood, particularly those derived from endothelial cells (EMPs) and platelets (PMPs).

Read More

    Author

    Scleroderma Queensland Support Group

    Archives

    May 2025
    April 2025
    March 2025
    February 2025
    January 2025
    December 2024
    November 2024
    October 2024
    September 2024
    August 2024
    July 2024
    June 2024
    May 2024
    April 2024
    March 2024
    February 2024
    January 2024
    May 2023
    April 2023
    March 2023
    February 2023
    January 2023
    December 2022
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    February 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    March 2020

    Categories

    All
    Announcements
    Community
    Members Stories
    Research
    Resources
    Scleroderma
    Support
    Support Group Meetings
    Useful Links

Scleroderma ​Association of Queensland
ABN 91 905 099 795

​About Us | Members' Stories | Group Meetings | Become a Member
Donate now
Phone 0468 801 021  Email [email protected]
Postal Address 54 Avocado Lane, Maleny, QLD, 4552
©Scleroderma Association of Queensland. ​All rights reserved. Website by Grey and Grey. 
  • Home
  • About Us
    • Your Committee
    • Members' Stories
  • Become a Member
    • Printable Membership Form
    • Online Membership Form
  • Donations
  • RESEARCH
  • FUNDRAISING
  • News
  • EVENTS
  • Group Meetings
  • GET SUPPORT
  • RESOURCES
  • Contact Us
  • Newsletter